Acute Myeloid Leukemia
Conditions
Brief summary
In recent years, multiple factors have strongly impacted the epidemiology of infections in patients with acute myeloid leukemia. On the one hand, the availability of new effective antileukemic drugs (i.e. venetoclax, FLT-3 inhibitors, CPX-351) have expanded the pharmacological armamentarium. On the other hand, first, many of them inhere drug-drug interactions with azoles and fluoroquinolones, facing clinicians with the choice of whether to administer antimicrobial prophylaxis or not. Secondly, there is an increase in infections due to multi-resistant agents from both the bacterial and fungal field. Third, the onset of a viral pandemic that had high relevance in these patients in terms of morbidity and mortality. The aim of this survey is to collect information on the largest possible sample of patients with AML during induction/consolidation/relapsed-refractory treatment, regarding bacterial, viral, fungal infections. We will evaluate the incidence of the various types of infection in relation to the type of treatment that patients will undergo, in order to identify what should be the best antimicrobial prophylactic approach in each subset of patients.
Interventions
OTHERdata analysis
follow up after 15 months
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to sign the consent form * Age ≥18 years * New diagnosis of AML (only cases diagnosed after 01/03/2025), APL are included * Patients not elegible to any kind of chemotherapy but only best supportive care (BSC) * AML patients treated with induction treatment, consolidation treatment, or relapsed/refractory (for these latter patients the first diagnosis must not be prior to March 01, 2025) * All kind of infectious diseases, including parasites. * Clincally or microbiologically diagnosed infections, including FUO
Exclusion criteria
* Hematological diseases, other than AML * Patients with an AML diagnosis prior to March 2025 but who relapsed during the period under examination * Patients relapsed after allo or auto-HSCT (Inclusion of post-transplant patients would create an evaluation bias due to the immunological alterations that the transplant procedure causes)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of bacterial/fungal/viral infections in AML patients | 18 months | To evaluate the incidence of bacterial/fungal/viral infections in AML patients undergoing induction, consolidation or salvage chemotherapy. |
Countries
Italy
Contacts
Primary ContactLIVIO PAGANO
Outcome results
None listed